Allergic rhinitis vaccination website launched

RNS Number : 4210E

Allergy Therapeutics PLC

06 April 2011

 



6 April 2011

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

Allergic rhinitis vaccination website launched

12 million Britons suffering from hay fever could benefit from vaccination

Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, has launched a website to promote the use of hay fever vaccination in the UK, (www.pollinex.com).

Although widely available across Western Europe and the US, historically, severe hay fever sufferers in the UK have had restricted access to curative vaccination treatment. Allergy Therapeutics' new website will attempt to educate hay fever sufferers, parents of young sufferers and GPs about the symptoms and treatment options increasingly available in the UK.

In the UK 20% of the population suffer from seasonal allergic rhinitis triggered by tree and grass pollen during spring and summer, imposing a strain on social lives, school performance and work productivity.¹ This percentage of the population is set to grow at an average rate of 5% per annum in Europe, the US and Japan.²

Allergy Therapeutics' website offers hay fever sufferers and GPs information on how to access vaccination, and the benefits of such treatment versus current treatment options. For moderate to severe cases of allergic rhinitis the Company's Pollinex^® portfolio offers a much more convenient and effective treatment regime than is currently available. Pollinex^® is the only registered subcutaneous immunotherapy available in the UK and consists of only 6 injections which can be administered in as little as 5 weeks.

Manuel Llobet, CEO of Allergy Therapeutics, commented:

"Thousands of people suffering from severe hay fever in the UK are unaware of the option of vaccination. We hope that our Pollinex.com website will provide a valuable tool for people suffering from allergies across the UK, allowing them to find the correct treatment solution that addresses the underlying cause of allergies, not just the symptoms."

¹ www.pollinex.com

² Nomura Code Securities research

For further information

Allergy Therapeutics	[phone]
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
www.allergytherapeutics.com
Financial Dynamics	[phone]
Ben Brewerton/ Susan Quigley

About Allergy Therapeutics

Allergy Therapeutics plc is a London Stock Exchange (AIM) listed, integrated specialist pharmaceutical company focused on allergy vaccination. It has a growing, profitable business achieving sales of allergy vaccines of £41 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.

About Allergy Vaccination

Allergy vaccination or immunotherapy is an effective way of modifying or avoiding disease by influencing the immune system.  It is essentially a reinforcement of the body's own defence mechanisms and is similar to preventative vaccination against infectious disease; an area of medicine that has met with spectacular success.  In allergy vaccination the mechanism is regarded as a correction of the immune system towards a more normal, non-allergic, response.

Allergy vaccination treats the underlying cause of the problem and provides a patient benefit which can be long lasting.  The World Health Organisation recognises allergy vaccination as the only treatment to target the immunological cause of allergy with the ability to modify disease progression (to more severe allergy and to asthma), decreasing symptoms in the short term and offering long term anti-inflammatory benefits which prevent the development of persistent disease.  Allergy vaccination, therefore, has the potential of offering patients a cure for their disease.

 

END

 

 

NRABBGDSLSGBGBL